| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb141b396e502bfce986c491d722e401 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-55 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-755
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-715
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-755
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2019-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1cd10d8a42e2d32a6182e54c70ce58da
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e7c74aee381d348fb1bf6b59a6f7aa1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17bc4bf617df35a928dfba5a6931bc87
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa0b1dfd1e079528619be784834573d5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b0495830833532d8987269ef554edb7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_66546bb5f269c3ce0bb9405219d315d0 |
| publicationDate |
2021-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2021094995-A1 |
| titleOfInvention |
Methods and compositions for treating cancer with ecm-affinity peptides linked to cytokines |
| abstract |
The methods and compositions described herein address the need in the art by providing compositions and methods for a therapy with a cytokine that is specifically targeted to and/or retained intra- or peri-tumorally, limiting systemic exposure and reducing side-effects. Accordingly, aspects of the disclosure relate to a composition comprising an immunotherapeutic antibody operatively linked to an extracellular matrix (ECM)-affinity peptide. An ECM-affinity peptide is one that has affinity for an extracellular matrix protein. |
| priorityDate |
2018-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |